When Americans talk about why prescription dr-gs cost so much, we often point fingers at pharmaceutical companies. But behind the scenes, a quiet and far more insidious force drives prices higher — Pharmacy Benefit Managers, or PBMs.
These middlemen were supposed to save us money by negotiating discounts and managing benefits between dr-gmakers, pharmacies, and insurance companies. Instead, they’ve built a cartel-like empire that manipulates prices, restricts access, and drains billions from patients and small pharmacies alike.
Three PBMs — CVS Caremark, Express Scripts, and OptumRx — now control nearly 80 percent of the prescription dr-g market. That’s not competition. That’s consolidation, and it gives them unchecked power to dictate what dr-gs Americans can take and how much we pay for them.
Here’s how the scheme works: PBMs negotiate secret rebates with dr-g manufacturers in exchange for preferred placement on insurance formularies. The larger the rebate, the more likely a dr-g will be covered — even if a cheaper or more effective alternative exists. But those rebates don’t go to patients. Instead, PBMs and insurers often pocket the difference, leaving patients at the pharmacy counter paying inflated copays or list prices.
Independent pharmacies suffer too. PBMs reimburse them below cost, while steering patients to their own mail-order or corporate-owned pharmacies. Many small-town pharmacies — often the only healthcare access point for miles — have closed under this pressure.
It’s legalized extortion wrapped in healthcare jargon.
The result? A system where everyone but the patient profits. Dr-gmakers inflate prices to fund rebates. PBMs boast about “savings” that never reach consumers. Insurers look the other way because they share in the cut. And the average American pays more for prescription dr-gs than anyone else on Earth.
The good news is that lawmakers are finally paying attention. Bipartisan bills in Congress and state legislatures aim to require transparency, ban spread pricing, and force rebates to flow directly to patients. But reform will fail unless regulators confront the core problem: PBMs have become too big, too secretive, and too conflicted to serve the public good.
The United States cannot claim to have a free market in healthcare when three corporations act as gatekeepers to every pill that reaches a patient. We broke up oil trusts and telecom monopolies before. It’s time to do the same for the PBM cartel.
Because healthcare should serve people, not middlemen.